Thanks for the opportunity. This is Rahul Agarwal from Everflow Capital. On the international business, you ment ioned that the EU -CDMO order book is going from INR 100 crores to INR 700 crores to INR 800 crores. Is this the total cumulative number or is this an annualized number you are targeting over the next few years? And what sort of scale do you see in the international business over the next three years to four years?
Got it. And one last question on the insulin bit. You mentioned that th ere's been a bit of a delay in the estimates, but you'd expect the numbers to start coming in from November. Did we hear that right? And so the full impact should be visible in Q4 with the innovator locating that market?